Sintx Technologies, INC

SINTX Technologies announced it has regained compliance with Nasdaq's minimum stockholders equity requirement, closing a previously disclosed deficiency matter.

SINTX Technologies provides a mid-year 2026 business update, detailing progress in its SiNAPTIC Foot & Ankle Implant System commercialization, industrial order fulfillment, and strategic platform expansion.

SINTX Technologies has engaged Southern Metrics Consulting, led by MedTech veteran Chris Lyons, to manage a new program focused on identifying and pursuing strategic opportunities to enhance stockholder value.

SINTX Technologies finalized a letter agreement to resolve outstanding warrants and abeyance shares, impacting its capital structure and equity position.

SINTX Technologies announced a $4.5 million private placement of units, including common stock and warrants, to fund general corporate purposes.

SINTX Technologies received a notice from Nasdaq for failing to meet minimum stockholders equity requirements, with 45 days to submit a compliance plan.

SINTX Technologies reported increased revenue for Q2 2026, but also highlighted substantial doubt about its ability to continue as a going concern, alongside significant operating losses.

SINTX Technologies reports Q3 2025 results, highlighting a strategic shift to biomedical devices, FDA clearance for a new foot and ankle system, and ongoing capital raises amidst declining revenue.

SINTX Technologies reported a wider net loss in Q2 2025 as it strategically shifts focus from industrial to high-margin silicon nitride biomedical devices, despite reduced operating expenses.

SINTX Technologies reports a net loss for Q1 2025, while strategically shifting focus towards biomedical applications and streamlining operations.

SINTX Technologies reported its Q3 2024 financial results, including a net loss, and announced a strategic shift towards the medical device sector, while ceasing operations at its armor plant.

SINTX Technologies saw a significant increase in revenue in the second quarter of 2024, but the company still experienced a net loss and is taking steps to improve operational efficiency.

SINTX Technologies reports a significant revenue decline in 2025 due to a strategic shift away from low-margin OEM contracts towards proprietary silicon nitride biomedical devices, while securing FDA clearance for a new foot and ankle system.

SINTX Technologies reports a net loss for fiscal year 2024 while strategically shifting focus towards biomedical applications and streamlining operations.

SINTX Technologies' 10-K filing details its business in advanced ceramics, including biomedical, technical, and antipathogenic applications, while also outlining measures to prevent hostile takeovers.

Sintx Technologies, Inc. reports a transaction where President Robert Ryan Elmore acquired 4,910 shares of common stock.

Sintx Technologies Director Jay M. Moyes acquired 1,000 shares of common stock at $2.91 per share, increasing his direct beneficial ownership to 4,000 shares.

Sintx Technologies Director Mark Lewis Anderson has filed a Form 4 indicating a planned acquisition of 3,000 shares of common stock at $3.02 per share on February 18, 2026, under a Rule 10b5-1 trading plan.

Sintx Technologies' CFO, Kevin Trask, received a grant of 60,000 Restricted Stock Units under the company's 2025 Equity Incentive Plan.

Sintx Technologies' Chairman, President, and CEO, Eric K. Olson, was granted 100,000 restricted stock units under the company's 2025 Equity Incentive Plan.

Sintx Technologies, Inc. granted 75,000 Restricted Stock Units to Chief Investment Officer Gregg R. Honigblum, aligning executive incentives.

SINTX Technologies, Inc. announced its upcoming annual meeting of stockholders on September 4, 2025, to vote on director elections, auditor ratification, executive compensation, and a new 2025 Equity Incentive Plan.

SINTX Technologies is strategically shifting its focus to the medical device sector, appointing a new Chief Strategy Officer, and implementing cost-reduction measures.

SINTX Technologies is holding its annual stockholder meeting on December 19, 2024, to vote on key proposals including the election of a director, ratification of auditors, executive compensation, and an amendment to the equity incentive plan.

SINTX Technologies is asking stockholders to approve a reverse stock split authorization to meet Nasdaq's minimum bid price requirement and maintain its listing.

SINTX Technologies plans to offer units consisting of common stock or pre-funded warrants, along with Class E and Class F warrants, aiming to raise up to $5 million.

Bleichroeder LP, through Bleichroeder Holdings LLC and Andrew Gundlach, has reported beneficial ownership of 9.99% of SINTX Technologies Inc. common shares, including shares issuable upon warrant exercise.

Laurence W. Lytton and the Lytton-Kambara Foundation have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in SINTX Technologies, Inc.

Stonepine Capital Management, LLC and affiliated entities report beneficial ownership of 9.9% of SINTX Technologies, Inc. common stock.

Gregg Richard Honigblum has reported a 5.0% beneficial ownership stake in SINTX Technologies, Inc., holding 201,067 shares of common stock as of December 8, 2025.

Virtus Wealth Solutions LLC reported a 5.3% beneficial ownership in Sintx Technologies, Inc. as of September 25, 2025, though its stake has since fallen below 5%.

Sinaptic Holdings, LLC has reported a 7.2% beneficial ownership stake in Sintx Technologies, Inc., comprising common stock and vested warrants.